https://www.selleckchem.com/pr....oducts/1-phenyl-2-th
Chronic kidney disease (CKD) is a risk factor for atherosclerotic cardiovascular disease (ASCVD). American cardiovascular societies consider CKD a risk-enhancing factor that supports statin therapy in intermediate-risk patients aged 40-75years. In contrast, European cardiovascular societies recommend statins for all middle-aged adults with CKD. The Kidney Disease Improving Global Outcomes lipid management guideline for CKD recommends statin therapy for all patients with CKD 50years. Clinical implications for these differ
Like
Comment
Share
